

## D-Chiro-Inositol Bibliography

### Diabetes

#### Animal

1. Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin-diabetic rats. Fonteles, M.C., Almeida, M.Q. and Larner, J. *Horm. Metabol. Res.* 32: 129-132 (2000).
2. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type II diabetic rats compared to Wistar controls. Sun T., Heimark D., et al. *BBRC*; 2002; 293: 1092-98.
3. Chiroinositol deficiency and insulin resistance II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant Rhesus monkeys. H.K. Ortmeyer, L.C. Huang, L. Zhang, B.C. Hansen and J. Larner. *Endocrinol.* 132: 646-651 (1993).
4. Chiroinositol deficiency and insulin resistance III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats *in vivo*. L.C. Huang, M.C. Fonteles, D.B. Houston, C. Zhang and J. Larner. *Endocrinol.* 132: (2) 652-657 (1993).
5. Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiro-inositol is directly associated with insulin resistance in spontaneously diabetic Rhesus monkeys. H.K. Ortmeyer, N.L. Bodkin, K. Lilley, J. Larner and B.C. Hansen. *Endocrinol.* 132: 640-645 (1993).
6. Effects of D-chiro-inositol added to a meal on plasma glucose and insulin in hyperinsulinemic Rhesus monkeys. H.K. Ortmeyer, J. Larner and B.C. Hansen. *Obesity Research*, 3: 605S-608S (1995).
7. *In vivo* chiro-inositol metabolism in the rat: A defect in chiro-inositol synthesis from myo-inositol and an increased incorporation of chiro-[<sup>3</sup>H]inositol into phospholipid in the type II diabetic Goto-Kakizati (G.K.) Rat. Y. Pak, Piccariello, T., Farese, R.V. and J. Larner, *Molecules and Cells* Vol. 8, 3: 301-309 (1998).
8. Infusion of pH 2.0 D-chiro-inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycemia. M.C. Fonteles, L.C. Huang and J. Larner, *Diabetologia* 39: 731-734 (1996).
9. Insulin stimulates the biosynthesis of chiro-inositol-containing phospholipids in a rat fibroblast line expressing the human insulin receptor. Y. Pak, C.R. Paule, Y-D. Bao, L.C. Huang and J. Larner. *PNAS*, 90: 7759-7763 (1993)

10. Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol containing insulin mediator is defective in adipocytes of insulin-resistant type II diabetic Goto-Kakizaki rats. R.V. Farese, M.L. Standaert, K. Yamada, L.C. Huang, C. Zhang, D.R. Cooper, Z. Wang, S. Suzuki, T. Toyota and J. Larner, Proc. Nat'l. Acad. Sci. (USA), 91: 11040-11044 (1994).
11. The renal excretion of inositol by normal and diabetic rats. W.H. Daughaday and J. Larner. J. Clin. Invest 33: 1075-1080 (1954).

#### Human

1. Chiro-inositol deficiency and insulin resistance. A comparison of the chiro-inositol and the myo-inositol containing insulin mediators isolated from urine, hemodialysate and muscle of control and type II diabetic subjects. I. Asplin, G. Galasko and J. Larner. Proc. Nat'l Acad. Sci. 90: 5924-5928 (1993).
2. Fasting decreases the content of D-chiro-inositol in human skeletal muscle Shashkin P, Huang LC, Larner J, Vandenhoff GE ,Katz A, Int. J.Diab. Res. 3: 163-169 (2002).
3. Fasting decreases the content of D-chiro-inositol in human skeletal muscle Shashkin P, Huang LC, Larner J, Vandenhoff GE ,Katz A, Int. J.Diab. Res. 3: 163-169 (2002).
4. The renal excretion of inositol in normal and diabetic human beings. W.H. Daughaday and J. Larner. J. Clin. Invest. 33: 326-332 (1954).
5. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. S. Suzuki, H. Kawasaki, Y. Satoh, M. Ohtomo, M. Hirai, A. Hirai, S. Hirai, M. Onoda, M. Matsumoto, Y. Hinokio, H. Akai, J. Craig, J. Larner, T. Toyota. Diabetes Care, 17: (12) 1465-1468 (1994).
6. Urinary myo-inositol to chiro-inositol ratios and insulin resistance. J. Larner and J.W. Craig, Diab. Care 19: 76-78, (1996).

#### General

1. D-chiro-inositol and insulin resistance: An allosteric point of view Frontiers in Animal Diabetes Research p 211-234. Larner, J. E. Shafir, B. Hanson, Eds. (2002).
2. D-chiro-inositol in insulin action and insulin resistance-Old fashioned biochemistry still at work. Larner, J. Critical Review IUBMB Life 51: 139-148 (2001)
3. D-chiro-inositol-Its functional role in insulin action and its deficit in insulin resistance. Larner, J., E. Shafir, Ed. Gordon Smith Publ., Great Britain, Int. J. Exp. Diab. Res. 3: 47-60 (2002).
4. Kok R.D., et al. Decreased relative brain tissue levels of inositol in fetal hydrocephalus. 2003; Amer. J. Obstetrics & Gynecology; 188 (4) : 978-980.
5. In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates

glycogen phosphorylase in Rhesus monkeys. H.K. Ortmeyer, N.L. Bodkin, B.C. Hansen, and J. Larner. *J. Nutritional Biochem.* 6: 499-503 (1995).

6. Insulin mediator--fact or fancy? J. Larner. *J. Cyclic Nuc. Res.* 8: (5) 289-296 (1982).
7. Insulin mediators and the mechanism of insulin action. G. Romero and J. Larner. *Adv. Pharm.* 24: 21-50 (1993).
8. Low urinary chiro-inositol excretion in non-insulin dependent diabetes mellitus. A.S. Kennington, C.R. Hill, J. Craig, C. Bogardus, I. Raz, H.K. Ortmeyer, B.C. Hansen, G. Romero and J. Larner. *New Eng. J. Med.*, Vol. 323, 6: 373-378 (1990).

### **Reproductive Function**

1. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. Nestler J.E., et al. *N. Engl. J. Med.* 1999; 340: 1314-1320.

### **Weight Management**

1. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphatase contains galactosamine and D-chiro-inositol. Larner J., et al. *Biochem. Biophys. Res. Commun.*; 1988; 151: 1416-26.

### **General**

1. Allosteric Activation of Protein Phosphatase 2C by D-chiro-inositol-Galactosamine, a Putative Mediator Mimetic of Insulin Action. D. L. Brautigan, M. Brown, S. Grindrod, G. Chinigo, A. Kruszewski, S. M. Lukasik, J. H. Bushweller, M. Horal, S. Keller, S. Tamura, D. B. Heimark, J. Price, A. N. Larner, and J. Larner *Biochemistry* 44:11067-11073 (2005).
2. Chiroinositol deficiency and insulin resistance: A clinical perspective. J.W. Craig, J. Larner and C.M. Asplin *Molec. Biol. of Diabetes. B. Draznin and D. LeRoith, Vol. 2, Eds. Humana Press, 343-362 (1994).*
3. Chiro-inositol deficiency and insulin resistance: A potentially correctable defect. J. Larner and L.C. Huang in Type II Diabetes: Glucose Homeostasis, Complications and Novel Therapeutics. Ross Products Div. Abbott Labs, Columbus, Ohio 58-60 (1995).
4. Circulating factors and insulin resistance. I. A novel myoinositol 1,2-cyclic phosphate phosphoglycan insulin antagonist from human plasma is elevated in noninsulin-dependent diabetes mellitus. G.T.F. Galasko, Y. Bao, S.J. Broomfield, N.M. Hooper, A.J. Turner and J. Larner, *J. Clin. Endo and Metab.*, 80: (8) 2419-2429 (1995).
5. Identification and characterization of chiroinositol-containing phospholipids from bovine liver. Y. Pak and J. Larner. *Biochem and Biophys Res. Commun.* 184: 1042-1047 (1992).
6. Isolation, Structure, Synthesis and Bioactivity of a Novel Putative Insulin Mediator: A Galactosamine Chiro-Inositol Pseudo-Disaccharide Mn<sup>2+</sup> Chelate with Insulin-Like Bioactivity Larner J, Price J D, Heimark D, Smith L, Rule G, Piccariello T, Fonteles MC, Pontes C, Vale D, and Huang LC *J. Med. Chem.* 46: 3283-3291 (2003).

## **Metabolic Syndrome**

1. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. N. R. F. Nascimento, L. M. A. Lessa, M. R. Kerntopf, C. M. Sousa, R. S. Alves, M. G .R. Queiroz, J. Price, D. B. Heimark, J. Larner, X. Du, M. Brownlee, A. Gow, C. Davis, and M. C. Fonteles. Proceedings of the National Academy of Sciences 103:218-223 (2006)
2. The effect of D-pinitol and D-chiro-inositol on caractogenesis and anti-oxidative effect in streptozotocin induced diabetic rats. Kim J.C. J Korean Ophthalmol Soc; 2005; 46 (11):1886-1893.